Mitral valve leaflet tissue (MVL)

The mitral valve leaflet tissue is a complex anatomical structure comprising the anterior and posterior leaflets that separate the left atrium from the left ventricle. It is primarily composed of an organized extracellular matrix (ECM) including collagen, elastin, and proteoglycans, which provide the mechanical strength and flexibility required to maintain unidirectional blood flow (StatPearls, 2023). The cellular components, mainly valvular interstitial cells (VICs) and valvular endothelial cells (VECs), play critical roles in maintaining tissue homeostasis and responding to mechanical strain. Pathological changes in this tissue, such as myxomatous degeneration or calcification, lead to clinical conditions like mitral valve prolapse and mitral regurgitation (American Heart Association, 2021). While the tissue itself is not a traditional molecular drug target, it is the primary site for surgical repair and transcatheter interventions. Pharmacological management typically targets the secondary effects of valve dysfunction, such as heart failure or arrhythmias, using diuretics, beta-blockers, or anticoagulants (JACC, 2020). Emerging research focuses on molecular pathways within the leaflet cells, such as TGF-beta signaling, to potentially slow the progression of valve remodeling.

Other names

Mitral valve leafletsBicuspid valve leafletsLeft atrioventricular valve leaflets

Pharmacological management focuses on reducing cardiac preload and afterload or preventing thromboembolism rather than direct molecular interaction with the leaflet tissue.